Expertise in
3
conditions

Catherine Ansquer

Nantes, FR 
Expertise in
3
conditions
Nantes, FR 

Overview

Catherine Ansquer practices practicing medicine in Nantes, France.

Ms. Ansquer is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Medullary Thyroid Carcinoma, Hyperparathyroidism, Pheochromocytoma, and Parathyroidectomy.

She is actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 3 clinical trials.

Gender

Female

Locations

Nantes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drugs: Lutathera, Octreotide
Study Phase: Phase 3
A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin
A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Drug, Other
Study Drugs: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) Peptide Receptor Radionuclide Therapy, CAPTEM (Capecitabine and Temozolomide), Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
Study Phase: Phase 3
A Randomized Phase III of Adjuvant Targeted Radionuclide Therapy With In111-Pentetreotide in Patients With Digestive Neuroendocrine Tumors After Complete Surgical Resection of Liver Metastases.
A Randomized Phase III of Adjuvant Targeted Radionuclide Therapy With In111-Pentetreotide in Patients With Digestive Neuroendocrine Tumors After Complete Surgical Resection of Liver Metastases.
Enrollment Status: Terminated
Publish Date: February 28, 2019
Intervention Type: Drug, Other
Study Phase: Phase 3
View 2 Less Clinical Trials

49 Total Publications

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
Journal: BMC cancer
Published: June 13, 2026

Frequently Asked Questions about Catherine Ansquer

Is Catherine Ansquer a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Catherine Ansquer is classified as an Advanced expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Catherine Ansquer participate in research or clinical trials?

Yes. Catherine Ansquer has published 49 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Catherine Ansquer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ansquer's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile